These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

595 related articles for article (PubMed ID: 16309985)

  • 1. RANKL-stimulated osteoclast-like cell formation in vitro is partially dependent on endogenous interleukin-1 production.
    Lee SK; Gardner AE; Kalinowski JF; Jastrzebski SL; Lorenzo JA
    Bone; 2006 May; 38(5):678-85. PubMed ID: 16309985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The 4-1BB ligand and 4-1BB expressed on osteoclast precursors enhance RANKL-induced osteoclastogenesis via bi-directional signaling.
    Yang J; Park OJ; Lee YJ; Jung HM; Woo KM; Choi Y
    Eur J Immunol; 2008 Jun; 38(6):1598-609. PubMed ID: 18421790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation.
    Häusler KD; Horwood NJ; Chuman Y; Fisher JL; Ellis J; Martin TJ; Rubin JS; Gillespie MT
    J Bone Miner Res; 2004 Nov; 19(11):1873-81. PubMed ID: 15476588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TRAF2 is essential for TNF-alpha-induced osteoclastogenesis.
    Kanazawa K; Kudo A
    J Bone Miner Res; 2005 May; 20(5):840-7. PubMed ID: 15824857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Receptor activator of NF-kappaB ligand induces the expression of carbonic anhydrase II, cathepsin K, and matrix metalloproteinase-9 in osteoclast precursor RAW264.7 cells.
    Fujisaki K; Tanabe N; Suzuki N; Kawato T; Takeichi O; Tsuzukibashi O; Makimura M; Ito K; Maeno M
    Life Sci; 2007 Mar; 80(14):1311-8. PubMed ID: 17306833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.
    Wang C; Steer JH; Joyce DA; Yip KH; Zheng MH; Xu J
    J Bone Miner Res; 2003 Dec; 18(12):2159-68. PubMed ID: 14672351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Possible involvement of protein kinases and Smad2 signaling pathways on osteoclast differentiation enhanced by activin A.
    Murase Y; Okahashi N; Koseki T; Itoh K; Udagawa N; Hashimoto O; Sugino H; Noguchi T; Nishihara T
    J Cell Physiol; 2001 Aug; 188(2):236-42. PubMed ID: 11424090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-1 plays an important role in the bone metabolism under physiological conditions.
    Lee YM; Fujikado N; Manaka H; Yasuda H; Iwakura Y
    Int Immunol; 2010 Oct; 22(10):805-16. PubMed ID: 20679512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitory effect of beta-cryptoxanthin on osteoclast-like cell formation in mouse marrow cultures.
    Uchiyama S; Yamaguchi M
    Biochem Pharmacol; 2004 Apr; 67(7):1297-305. PubMed ID: 15013845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Receptor activator of NF-kappaB ligand-stimulated osteoclastogenesis in mouse marrow culture is suppressed by zinc in vitro.
    Yamaguchi M; Uchiyama S
    Int J Mol Med; 2004 Jul; 14(1):81-5. PubMed ID: 15202020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-cells mediate an inhibitory effect of interleukin-4 on osteoclastogenesis.
    Mirosavljevic D; Quinn JM; Elliott J; Horwood NJ; Martin TJ; Gillespie MT
    J Bone Miner Res; 2003 Jun; 18(6):984-93. PubMed ID: 12817750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-7 is a direct inhibitor of in vitro osteoclastogenesis.
    Lee SK; Kalinowski JF; Jastrzebski SL; Puddington L; Lorenzo JA
    Endocrinology; 2003 Aug; 144(8):3524-31. PubMed ID: 12865334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone morphogenetic protein-2 enhances osteoclast formation mediated by interleukin-1alpha through upregulation of osteoclast differentiation factor and cyclooxygenase-2.
    Koide M; Murase Y; Yamato K; Noguchi T; Okahashi N; Nishihara T
    Biochem Biophys Res Commun; 1999 May; 259(1):97-102. PubMed ID: 10334922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Furosin, an ellagitannin, suppresses RANKL-induced osteoclast differentiation and function through inhibition of MAP kinase activation and actin ring formation.
    Park EK; Kim MS; Lee SH; Kim KH; Park JY; Kim TH; Lee IS; Woo JT; Jung JC; Shin HI; Choi JY; Kim SY
    Biochem Biophys Res Commun; 2004 Dec; 325(4):1472-80. PubMed ID: 15555594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-10 inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264.7 cells and mouse bone marrow cells.
    Mohamed SG; Sugiyama E; Shinoda K; Taki H; Hounoki H; Abdel-Aziz HO; Maruyama M; Kobayashi M; Ogawa H; Miyahara T
    Bone; 2007 Oct; 41(4):592-602. PubMed ID: 17627913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of p38 mitogen-activated protein kinase prevents inflammatory bone destruction.
    Mbalaviele G; Anderson G; Jones A; De Ciechi P; Settle S; Mnich S; Thiede M; Abu-Amer Y; Portanova J; Monahan J
    J Pharmacol Exp Ther; 2006 Jun; 317(3):1044-53. PubMed ID: 16501068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of osteoclasts by interleukin-1: divergent responsiveness in osteoclasts formed in vivo and in vitro.
    Fox SW; Fuller K; Chambers TJ
    J Cell Physiol; 2000 Sep; 184(3):334-40. PubMed ID: 10911364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual modulation of osteoclast differentiation by lipopolysaccharide.
    Zou W; Bar-Shavit Z
    J Bone Miner Res; 2002 Jul; 17(7):1211-8. PubMed ID: 12096834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JNK/c-Jun signaling mediates an anti-apoptotic effect of RANKL in osteoclasts.
    Ikeda F; Matsubara T; Tsurukai T; Hata K; Nishimura R; Yoneda T
    J Bone Miner Res; 2008 Jun; 23(6):907-14. PubMed ID: 18251700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
    Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH
    Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.